Bristol Myers Squibb | The Media Pub News

Bristol Myers Squibb showcases research advancing outcomes addressing hard-to-treat blood cancers and diseases across small molecule, biologic and cell therapies at ASH 2020

November 11, 2020

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401

Business, Education

UNCF, Bristol Myers Squibb announce second cohort of the Ernest E. Just Postgraduate Fellowship and extension of partnership through 2026

October 02, 2020

Fellowship program honors Dr. Just, a pioneering biologist and one of the most prominent African American scientists of the twentieth century WASHINGTON & PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #UNCF–The UNCF and Bristol Myers Squibb (NYSE: BMY) today announced the second cohort of the Ernest

Business, Healthcare

Bristol Myers Squibb provides update on Phase 3 IDHENTIFY trial in patients with relapsed or refractory acute myeloid leukemia

August 25, 2020

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AML—Bristol Myers Squibb (NYSE:BMY) today announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or

Business, Healthcare

Bristol Myers Squibb and the Bristol Myers Squibb Foundation commit $300 million to accelerate and expand health equity and diversity and inclusion efforts

August 12, 2020

Five–year commitment builds on long-standing investment in health equity PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol Myers Squibb (NYSE: BMY) and the Bristol Myers Squibb Foundation announced today a combined investment of $300 million as part of a series of commitments. For Bristol Myers Squibb

Business, Healthcare

Bristol Myers Squibb and bluebird bio announce submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for adults with relapsed and refractory multiple myeloma

July 30, 2020

BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BLUE #BMS—Bristol